Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 5:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: La Crosse, Wisconsin Clear all
Recruiting Phase 3 Interventional

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

NCT05407636
View directory record Official record
Conditions
AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV
Interventions
ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®)
Genetic · Biological
Lead sponsor
AbbVie
Industry
Eligibility
50 Years to 89 Years
Enrollment
714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
107
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 94 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jul 24, 2026, 5:20 PM EDT
Completed Phase 3 Interventional Results available

S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer

NCT00075764
View directory record Official record
Conditions
Breast Cancer
Interventions
anastrozole, fulvestrant
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Female only
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
418
States / cities
Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 289 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Jul 24, 2026, 5:20 PM EDT
Recruiting Phase 3 Interventional

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

NCT06492616
View directory record Official record
Conditions
Breast Cancer
Interventions
Elacestrant, Anastrozole, Letrozole, Exemestane, Tamoxifen
Drug
Lead sponsor
Stemline Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4,220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
170
States / cities
Daphne, Alabama • Chandler, Arizona • Gilbert, Arizona + 134 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 24, 2026, 5:20 PM EDT
Completed Phase 2 Interventional Results available

Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

NCT00404235
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
carboplatin, paclitaxel albumin-stabilized nanoparticle formulation
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
156
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 98 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Jul 24, 2026, 5:20 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults

NCT06047457
View directory record Official record
Conditions
Episodic Migraine
Interventions
Botulinum toxin type A, Placebo
Biological · Other
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
66
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 24, 2026, 5:20 PM EDT
Not listed Phase 3 Interventional Results available

Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

NCT00567580
View directory record Official record
Conditions
Prostate Cancer
Interventions
PBRT, PLNRT, AA, LHRH agonist
Radiation · Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
1,792 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
444
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Peoria, Arizona + 316 more
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Jul 24, 2026, 5:20 PM EDT
Completed Phase 2 Interventional

Everolimus in Treating Patients With Stage IV Melanoma

NCT00098553
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
everolimus
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
94
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 60 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2016 · Synced Jul 24, 2026, 5:20 PM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia

NCT07086976
View directory record Official record
Conditions
Autoimmune Haemolytic Anaemia
Interventions
rilzabrutinib, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
23
States / cities
Phoenix, Arizona • Tucson, Arizona • Duarte, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 24, 2026, 5:20 PM EDT
Completed Phase 3 Interventional Results available

Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy

NCT01099449
View directory record Official record
Conditions
Chemotherapeutic Agent Toxicity, Colorectal Cancer, Neuropathy, Neurotoxicity
Interventions
calcium gluconate, magnesium sulfate, placebo, oxaliplatin
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
404
States / cities
Fairbanks, Alaska • Antioch, California • Fairfield, California + 278 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Jul 24, 2026, 5:20 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Screening for High Frequency Malignant Disease

NCT05117840
View directory record Official record
Conditions
Lung Cancer
Interventions
Low-dose CT scan
Device
Lead sponsor
Guardant Health, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
12,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
125
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Anaheim, California + 105 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 24, 2026, 5:20 PM EDT
Completed Not applicable Interventional

Tetracycline in Preventing Skin Rash in Patients Who Are Receiving Drugs Such as Gefitinib and Cetuximab for Cancer

NCT00091247
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
tetracycline hydrochloride, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
69
States / cities
Aurora, Illinois • Joliet, Illinois • Urbana, Illinois + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Jul 24, 2026, 5:20 PM EDT
Completed Phase 3 Interventional Results available

Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors

NCT00566852
View directory record Official record
Conditions
Cognitive/Functional Effects, Metastatic Cancer, Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Memantine, Placebo, Whole brain radiation therapy
Drug · Other · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
229
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 183 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2017 · Synced Jul 24, 2026, 5:20 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol

NCT02227784
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Evacetrapib, Atorvastatin, Ezetimibe, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
61
States / cities
Huntsville, Alabama • Mesa, Arizona • Phoenix, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Jul 24, 2026, 5:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sleeper Stretch in CrossFit Participants

NCT06720155
View directory record Official record
Conditions
Shoulder Pain
Interventions
Sleeper stretch, Standard workout
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
La Crosse, Wisconsin • Onalaska, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Jul 24, 2026, 5:20 PM EDT
Completed Phase 2 Interventional Results available

A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension

NCT00522925
View directory record Official record
Conditions
Hypertension
Interventions
PS433540, placebo
Drug
Lead sponsor
Ligand Pharmaceuticals
Industry
Eligibility
30 Years to 80 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
15
States / cities
Tempe, Arizona • Lincoln, California • Long Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2011 · Synced Jul 24, 2026, 5:20 PM EDT
Completed Phase 2 Interventional

Docetaxel, Carboplatin, and Pegfilgrastim in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer

NCT00107510
View directory record Official record
Conditions
Breast Cancer
Interventions
pegfilgrastim, carboplatin, docetaxel, conventional surgery
Biological · Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
120
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 78 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2016 · Synced Jul 24, 2026, 5:20 PM EDT
Completed Phase 2 Interventional Results available

Gemcitabine and Carboplatin With or Without AZD2171 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00326599
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, cediranib maleate, gemcitabine hydrochloride
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
154
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 95 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Jul 24, 2026, 5:20 PM EDT
Completed Phase 3 Interventional Results available

Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ

NCT00438659
View directory record Official record
Conditions
Breast Cancer, Dermatologic Complications, Radiation Toxicity, Skin Reactions Secondary to Radiation Therapy
Interventions
mometasone furoate, placebo
Drug · Other
Lead sponsor
North Central Cancer Treatment Group
Network
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
189
States / cities
Aurora, Illinois • Bloomington, Illinois • Canton, Illinois + 116 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2016 · Synced Jul 24, 2026, 5:20 PM EDT
Completed Phase 3 Interventional

A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

NCT06065540
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
2,734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
100
States / cities
Birmingham, Alabama • Pelham, Alabama • Phoenix, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 24, 2026, 5:20 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults

NCT03732638
View directory record Official record
Conditions
Migraine
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
93
States / cities
Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 86 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Jul 24, 2026, 5:20 PM EDT
Active, not recruiting Phase 3 Interventional Results available

S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

NCT00070564
View directory record Official record
Conditions
Breast Cancer
Interventions
pegfilgrastim, AC regimen, cyclophosphamide, doxorubicin hydrochloride, paclitaxel
Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
3,294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2027
U.S. locations
539
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 369 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Jul 24, 2026, 5:20 PM EDT
Completed Phase 3 Interventional Results available

A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)

NCT05514535
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Obesity
Interventions
Semaglutide, Insuline glargine U100 (reduced), Insuline glargine U100 (titrated)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
573 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
145
States / cities
Sheffield, Alabama • Glendale, Arizona • Mesa, Arizona + 113 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Jul 24, 2026, 5:20 PM EDT
Completed Phase 4 Interventional

A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients

NCT00240448
View directory record Official record
Conditions
Hypertension
Interventions
telmisartan 80 mg/hydrochlorothiazide 25 mg, valsartan 160 mg/hydrochlorothiazide 25 mg, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
100
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2013 · Synced Jul 24, 2026, 5:20 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine

NCT02867709
View directory record Official record
Conditions
Migraine, With or Without Aura
Interventions
Ubrogepant, Placebo-matching Ubrogepant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,686 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
109
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Jul 24, 2026, 5:20 PM EDT